

4.0.03 DOC Cmte minutes

Atrial fibrillation (update) Committee meeting 14

Date: 23&24 November 2020, 14:30-17:30 both days

Location: Virtual meeting via Zoom

Minutes: Final

NICE National Institute for
Health and Care Excellence

Committee members present:		
Simon Mackenzie (SM) [Chair]		(Present for notes 1 – 8)
Neil Andrews (NA) [Topic advisor]		(Present for notes 1 – 8)
Matthew Bates (MB)		(Present for notes 1 – 8)
Antony Chuter (AC)		(Present for notes 1 – 4)
Nazish Khan (NK)		(Present for notes 1 – 8)
Paulus Kirchhof (PK)		(Present for notes 1 – 8)
Thomas McAnea (TM)		(Present for notes 1 – 8)
Irene McGill (IM)		(Present for notes 1 – 8)
Chakravarthi Rajkumar (CR)		(Present for notes 1 – 8)
Yohan Samarasinghe (YS)		(Present for notes 1 – 8)
Jaspal Taggar (JT)		(Present for notes 1 – 8)
Keith Tyndall (KT)		(Present for notes 1 – 8)

In attendance:		
Sharon Swain (SS)	Guideline Lead, NGC	(Present for notes 1 – 8)
Mark Perry (MP)	Senior Research Fellow, NGC	(Present for notes 1 – 8)
Nicole Downes (ND)	Research Fellow, NGC	(Present for notes 1 – 8)
Sophia Kemmis Betty (SKB)	Senior Health Economist, NGC	(Present for notes 1 – 8)
Giulia Zuodar (GZ)	Project Manager, NGC	(Present for notes 1 – 8)
Anne-Louise Clayton (ALC)	Senior Editor, NICE	(Present for notes 1 – 8)
Catrina Charlton (CC)	Guideline Commissioning Manager, NICE	(Present for notes 1 – 8)
Ian Mather (IM)	Business Analyst, NICE	(Present for notes 1 – 8)

4.0.03 DOC Cmte minutes

Apologies:	
Gerry Lee	GC member

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the fourteenth meeting on Atrial fibrillation (update). The Committee members and attendees introduced themselves.

The Chair outlined the objectives of the meeting, which included discussing the feedback from stakeholder consultation and reviewing the recommendations, research recommendations and guideline algorithms.

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion would cover all review questions.

No new declarations were received.

The Chair and a senior member of the Developer's team noted that the interests previously declared prevented PK from participating to amendments to the recommendations on anticoagulation and discontinuing anticoagulation, AF detection, non-ablative therapies. It was agreed that PK would withdraw for these discussions.

4. Stakeholder comments: anticoagulation

The GC discussed the stakeholder comments on anticoagulation.

PK did not attend the discussions on anticoagulation and discontinuing anticoagulation, as per decision outlined in section 2 above.

5. Stakeholder comments: anticoagulation: ablation

The GC discussed the stakeholder comments on ablation.

6. Stakeholder comments: bleeding risk tools

The GC discussed the stakeholder comments on bleeding risk tools.

7. Other stakeholder comments

The GC discussed miscellaneous stakeholder comments.

PK did not attend the discussions on AF detection, non-ablative therapies as

4.0.03 DOC Cmte minutes

per decision outlined in section 2 above.

8. Any other business

None.